• 1
    Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 55767.
  • 2
    Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 3750.
  • 3
    Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983; 1: 195205.
  • 4
    Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006; 45 Suppl 3: iii267.
  • 5
    Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980; 69: 5206.
  • 6
    Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC. A prospective study of Raynaud phenomenon and early connective tissue disease: a five-year report. Am J Med 1982; 72: 8838.
  • 7
    Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum 1985; 28: 8792.
  • 8
    Houtman PM, Kallenberg CG, Fidler V, Wouda AA. Diagnostic significance of nailfold capillary patterns in patients with Raynaud's phenomenon: an analysis of patterns discriminating patients with and without connective tissue disease. J Rheumatol 1986; 13: 55663.
  • 9
    Priollet P, Vayssairat M, Housset E. How to classify Raynaud's phenomenon: long-term followup study of 73 cases. Am J Med 1987; 83: 4948.
  • 10
    Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47: 63441.
  • 11
    Fitzgerald O, Hess EV, O'Connor GT, Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med 1988; 84: 71826.
  • 12
    Wollersheim H, Thien T, Hoet MH, Van Venrooij WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989; 19: 53541.
  • 13
    Gentric A, Blaschek MA, Le Noach JF, Johanet C, Jouquan J, Lamour A, et al. Serological arguments for classifying Raynaud's phenomenon as idiopathic. J Rheumatol 1990; 17: 117781.
  • 14
    Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, et al. Prognostic significance of anticentromere antibodies and anti–topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum 1991; 34: 6877.
  • 15
    Zufferey P, Depairon M, Chamot AM, Monti M. Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities: a six-year followup study. Clin Rheumatol 1992; 11: 53641.
  • 16
    Ter Borg EJ, Piersma-Wichers G, Smit AJ, Kallenberg CG, Wouda AA. Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. Semin Arthritis Rheum 1994; 24: 407.
  • 17
    Vayssairat M, Baudot N, Gaitz JP. Raynaud's phenomenon together with antinuclear antibodies: a common subset of incomplete connective tissue disease. J Am Acad Dermatol 1995; 32: 7479.
  • 18
    Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud's phenomenon: a longterm prospective study. J Rheumatol 1995; 22: 222632.
  • 19
    Landry GJ, Edwards JM, McLafferty RB, Taylor LM Jr, Porter JM. Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort. J Vasc Surg 1996; 23: 7685.
  • 20
    Hirschl M, Kundi M. Initial prevalence and incidence of secondary Raynaud's phenomenon in patients with Raynaud's symptomatology. J Rheumatol 1996; 23: 3029.
  • 21
    LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 15736.
  • 22
    Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006; 54: 197481.
  • 23
    Maricq HR, Gordon G, LeRoy EC. Studies in patients with connective tissue disorders. Bibl Anat 1977;( 16 Pt 2): 13541.
  • 24
    Maricq HR. Widefield capillary microscopy: technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 1981; 24: 115965.
  • 25
    Scussel Lonzetti L, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma [letter]. Arthritis Rheum 2001; 44: 7356.
  • 26
    Senecal JL, Henault J, Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis. J Rheumatol 2005; 32: 16439.
  • 27
    Raynaud M. Thèse de Médicine: De l'asphyxie locale et de la gangrène des extremités. Paris: Leclerc; 1862.
  • 28
    Wigley FW. Raynaud's phenomenon. New Eng J Med 2002; 347: 10018.
  • 29
    Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 15467.
  • 30
    Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 31
    Maricq HR. Comparison of quantitative and semiquantitative estimates of nailfold capillary abnormalities in scleroderma spectrum disorders. Microvasc Res 1986; 32: 2716.
  • 32
    Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 1988; 31: 37885.
  • 33
    Vazquez-Abad D, Wallace S, Senecal JL, Joyal F, Roussin A, Earnshaw WC, et al. Anticentromere autoantibodies: evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. Arthritis Rheum 1994; 37: 24852.
  • 34
    Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 195663.
  • 35
    Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9: R78.
  • 36
    Fritzler MJ. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006; 15: 4227.
  • 37
    Henault J, Tremblay M, Clement I, Raymond Y, Senecal JL. Direct binding of anti–DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 2004; 50: 326574.
  • 38
    Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti–RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005; 52: 242532.
  • 39
    Venables PJ. Overlap syndromes. In: HochbergMC, SilmanAJ, SmolenJS, WeinblattME, WeismanMH, editors. Rheumatology. Toronto: Elsevier; 2003. p. 152335.
  • 40
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 41
    Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13: 9116.
  • 42
    Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 44451.
  • 43
    Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998; 158: 595600.
  • 44
    Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al [letter]. Arthritis Rheum 2007; 56: 21023.
  • 45
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 398593.
  • 46
    Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 31122.
  • 47
    Chen Z, Silver R, Ainsworth S, Dobson R, Rust P, Maricq H. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984; 77: 81222.
  • 48
    Cutolo M, Pizzorni C, Tuccio M, Burroni A, Craviotto C, Basso M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 71926.
  • 49
    Ihata A, Shirai A, Okubo T, Ohno S, Hagiwara E, Ishigatsubo Y. Severity of seropositive isolated Raynaud's phenomenon is associated with serological profile. J Rheumatol 2000; 27: 168692.